Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas

Area of Science:

• Global Health
• Vaccinology
• Infectious Diseases

Background:

• Typhoid fever poses a significant disease burden, particularly affecting children in endemic regions of Asia and Africa.
• Recent advancements in vaccine technology have led to the development of effective typhoid interventions.

Purpose of the Study:

• To summarize the efficacy and impact of typhoid conjugate vaccine (TCV) in pediatric populations.
• To highlight the ongoing efforts and future needs for typhoid fever control.

Main Methods:

• Review of clinical trials by the Typhoid Vaccine Acceleration Consortium.
• Analysis of recent TCV introduction strategies in Pakistan, Liberia, and Zimbabwe.
• Assessment of data gaps concerning typhoid complications.

Main Results:

• Typhoid conjugate vaccine (TCV) demonstrated safety, immunogenicity, and efficacy in preventing blood culture-confirmed typhoid fever in African and Asian children.
• TCV has been successfully introduced in Pakistan, Liberia, and Zimbabwe through immunization campaigns and routine services.
• Ongoing efforts are crucial to address remaining data gaps, including typhoid complications, to guide future TCV implementation.

Conclusions:

• Large-scale TCV introduction, coupled with enhanced surveillance and investments in water, sanitation, and hygiene (WASH), is essential for reducing typhoid fever burden and mortality.
• Sustained global health efforts are necessary to protect vulnerable populations from typhoid fever.